Health Dept to Review Women Lung Cancer Research

Summary#

The Women and Lung Cancer Research and Preventive Services Act of 2025 is a proposed standalone law; it does not amend an existing Act. It would require the Secretary of Health and Human Services (HHS), consulting with the Secretaries of Defense and Veterans Affairs, to review lung cancer research and access to preventive services. Its stated goal is to identify opportunities to accelerate research, expand screening access, and improve public awareness.

  • HHS would review previous research, current federal research, and knowledge gaps on lung cancer in women and underserved populations across federal agencies.
  • The review would examine opportunities for collaborative research, including research on environmental and genomic factors and improvements in imaging.
  • It would examine opportunities to develop a national lung cancer screening strategy and a public education and awareness campaign; it does not require either to be created.
  • HHS would have to send Congress a report on the review within two years after the law takes effect.

What it means for you#

  • HHS, Defense, and Veterans Affairs: HHS must lead the interagency review and consult the Defense and Veterans Affairs secretaries.
  • Women and underserved populations: The bill does not directly change screening eligibility, provide screening or other services, or create a new benefit. For one part of the review, “underserved populations” means those meeting the U.S. Preventive Services Task Force’s recommended lung cancer screening eligibility criteria.
  • Researchers and the public: The bill calls for examining research and possible education efforts, but does not require new research projects or a public campaign.
  • Congress: HHS must submit the review report within two years. The bill does not say the report must be made public.

Money#

No cost estimate or funding amount is provided in the available material.

  • HHS must conduct the review and prepare the report, with consultation from Defense and Veterans Affairs. The bill does not estimate the staffing or other costs.
  • The bill does not appropriate money or require spending on screening services, research projects, or an awareness campaign.

What is unclear#

  • The bill does not define “underserved populations” beyond the screening eligibility criteria specified for one research topic, or define “preventive services.”
  • It does not set a method, milestones, or division of work for the interagency review.
  • It does not specify whether or how any identified opportunities would be funded or put into effect.
  • It does not set out how the screening strategy or public campaign would be developed if the review identifies them as opportunities.

Case for#

  • The review could identify gaps in federal research on lung cancer in women and eligible underserved populations.
  • Examining research across agencies could help identify opportunities for collaboration rather than leaving each agency’s work isolated.
  • Considering screening access and public education alongside research could help Congress see a broader range of possible responses.

Case against#

  • The bill requires a review and report, but does not require agencies to act on the recommendations or create screening or education programs.
  • It gives no funding or staffing estimate, so the resources needed for the review are unknown.
  • The bill sets a two-year deadline for the report but does not require interim updates or specify how progress would be measured.